250 related articles for article (PubMed ID: 25936332)
1. First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias.
Stefanutti C; D'Alessandri G; Petta A; Harada-Shiba M; Julius U; Soran H; Moriarty PM; Romeo S; Drogari E; Jaeger BR;
Atheroscler Suppl; 2015 May; 18():241-50. PubMed ID: 25936332
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
3. The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.
Virani SS
Tex Heart Inst J; 2016 Aug; 43(4):313-4. PubMed ID: 27547139
[No Abstract] [Full Text] [Related]
4. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
5. Practice variation in long-term secondary stroke prevention in The Netherlands.
van Schaik SM; de Vries BS; Weinstein HC; Visser MC; Van den Berg-Vos RM
J Stroke Cerebrovasc Dis; 2015 Mar; 24(3):566-72. PubMed ID: 25543189
[TBL] [Abstract][Full Text] [Related]
6. [LDL apheresis: an update and overview. LDL apheresis in Sardinia, Italy (SMILDLa)].
Stefanutti C; Di Giacomo S; Morozzi C
G Ital Nefrol; 2012; 29 Suppl 54():S14-8. PubMed ID: 22388823
[TBL] [Abstract][Full Text] [Related]
7. Survey of trends and gaps in dermatologists' cardiovascular screening practices in psoriasis patients: Areas still in need of improvement.
Manalo IF; Gilbert KE; Wu JJ
J Am Acad Dermatol; 2015 Nov; 73(5):872-4.e4. PubMed ID: 26475543
[No Abstract] [Full Text] [Related]
8. HEART UK consensus statement on Lipoprotein(a): A call to action.
Cegla J; Neely RDG; France M; Ferns G; Byrne CD; Halcox J; Datta D; Capps N; Shoulders C; Qureshi N; Rees A; Main L; Cramb R; Viljoen A; Payne J; Soran H;
Atherosclerosis; 2019 Dec; 291():62-70. PubMed ID: 31704552
[TBL] [Abstract][Full Text] [Related]
9. How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines.
Orringer CE
Methodist Debakey Cardiovasc J; 2019; 15(1):16-22. PubMed ID: 31049145
[TBL] [Abstract][Full Text] [Related]
10. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
Reiner Z
Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
[No Abstract] [Full Text] [Related]
11. Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014.
Langsted A; Freiberg JJ; Nordestgaard BG
Atherosclerosis; 2017 Feb; 257():9-15. PubMed ID: 28038381
[TBL] [Abstract][Full Text] [Related]
12. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
Stock J
Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
[No Abstract] [Full Text] [Related]
13. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.
Goldberg SL; Akard LP; Dugan MJ; Faderl S; Pecora AL
J Oncol Pract; 2015 May; 11(3):e398-404. PubMed ID: 25758446
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
15. History of lipidology and lipoprotein apheresis.
Julius U
Atheroscler Suppl; 2017 Nov; 30():1-8. PubMed ID: 29096824
[TBL] [Abstract][Full Text] [Related]
16. The MAURO study: baseline characteristics and compliance with guidelines targets.
Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
[TBL] [Abstract][Full Text] [Related]
19. Factors Affecting Pediatric Dyslipidemia Screening and Treatment.
Herrington L; Susi A; Gorman G; Nylund CM; Hisle-Gorman E
Clin Pediatr (Phila); 2019 May; 58(5):502-510. PubMed ID: 30793626
[TBL] [Abstract][Full Text] [Related]
20. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
; ;
Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
[No Abstract] [Full Text] [Related]
[Next] [New Search]
